Accutest Research Laboratories, a leading independent and internationally accredited Contract Research Organization (CRO), has formed a strategic partnership with Fox Chase Cancer Center - Temple Health for joint work on clinical trials.
Bob Luebbe: Many years ago a system was one or two pieces of equipment put together. What we do now are really bring a whole lot of different pieces together. It used to be just a bin and a blender or a bin and a discharge station, a bin and a fill station. Now it's filling, it's blending, it's discharging, its containment.
Horizon Discovery Group plc (LSE:HZD) (Horizon), the international life science company supplying research tools and services to organizations engaged in genomics research and the development of personalized medicines, and Axol Bioscience Ltd (Axol), a biotechnology company specializing in the use of stem cell technology to manufacture disease relevant cell based assay systems, announce they have formed a strategic partnership for the delivery of off-the-shelf and on-demand genomically modified and differentiated iPS cells.
RWS Holdings plc announce preliminary results for the year ended 30 September 2015.
We are thrilled to be winners of the Golden Bridge Trade & Export Awards 2015 in the Best British Medium-sized Company category.
Corporate Translations Inc (CTi), the world's leading life sciences translation and linguistic validation provider, has been acquired by RWS, the world's leading provider of intellectual property support services.
Johnson Matthey (LSE: JMAT), a leading provider of pharmaceutical services, active pharmaceutical ingredients (APIs) and catalyst technologies, has announced completion of an acquisition of pharmaceutical manufacturing capacity in Scotland, U.K. The 109,000 sq. metre site was acquired to meet increasing demand for custom pharmaceutical services and active ingredients utilising enhanced manufacturing capabilities.
Johnson Matthey (LSE: JMAT), a leading provider of pharmaceutical services, active pharmaceutical ingredients (APIs) and catalyst technologies, has announced completion and commissioning of new high containment facilities for potent product manufacture at its Edinburgh, UK site (Macfarlan Smith).
Johnson Matthey (LSE: JMAT), a leading provider of pharmaceutical services, active pharmaceutical ingredients (APIs) and catalyst technologies, has today unveiled the distinctive new branding for its Fine Chemicals Division. The new brand brings together Johnson Matthey’s broad chiral and catalysis technologies, its world-leading opiates and narcotics capabilities, and global API development, life cycle management and manufacturing expertise.
Johnson Matthey (LSE: JMAT), a leading provider of pharmaceutical services, active pharmaceutical ingredients (APIs) and catalyst technologies, has been recognised in the 2015 CMO Leadership Awards for the Reliability and Regulatory Track record of its Pharma Services to the Biotech Industry.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.